fluticasone propionate controlled release (EP-104) / Syreon, Eupraxia Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fluticasone propionate controlled release (EP-104) / Eupraxia Pharma
2021-000859-39: A Phase 2 Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients with Osteoarthritis of the Knee

Not yet recruiting
2
300
Europe
EP-104IAR, Powder and solution for suspension for injection
Eupraxia Pharmaceuticals Inc., Eupraxia Pharmaceuticals Inc.
Osteoarthritis of the knee, Knee osteoarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT04120402: Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

Completed
2
318
Europe, RoW
EP-104IAR 25 mg, Vehicle
Eupraxia Pharmaceuticals Inc., NBCD A/S
Osteoarthritis, Knee
05/23
06/23
NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
24
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
11/24
11/24

Download Options